<DOC>
	<DOCNO>NCT00499707</DOCNO>
	<brief_summary>The purpose 32 week study demonstrate fixed-dose combination treatment rosiglitazone/metformin safely effectively control glycemia first line oral therapy subject type 2 diabetes . The primary objective study demonstrate superiority rosiglitazone/metformin compare rosiglitazone metformin .</brief_summary>
	<brief_title>Efficacy Safety Study Rosiglitazone/Metformin Therapy v Rosiglitazone Metformin Type 2 Diabetes Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>18 70 year age Clinical diagnosis type 2 diabetes HbA1c &gt; 7.5 % 11 % FPG &lt; 270mg/dL ( 15mmol ) Current treatment diet and/or exercise alone , 15 day antidiabetic medication insulin within 12 week screen Clinically significant renal hepatic disease Presence anemia Presence unstable severe angina , coronary insufficiency , congestive heart failure require therapy Systolic blood pressure &gt; 170mmHg diastolic blood pressure &gt; 100mmHg , antihypertensive treatment Chronic disease require intermittent chronic treatment corticosteroid Any female lactating , pregnant , plan become pregnant History hepatocellular reaction , severe edema medically serious fluid relate event associate thiazolidinedione Presence acute chronic metabolic acidosis History diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HbA1c</keyword>
	<keyword>Drug-naive</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>